Synairgen plc (LON:SNG – Get Free Report) shares dropped 18.7% during trading on Thursday . The stock traded as low as GBX 4.51 ($0.06) and last traded at GBX 4.51 ($0.06). Approximately 128,570 shares traded hands during trading, a decline of 62% from the average daily volume of 341,639 shares. The stock had previously closed at GBX 5.55 ($0.07).
Synairgen Trading Down 16.3 %
The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35. The business’s 50-day moving average is GBX 6.34 and its two-hundred day moving average is GBX 5.96. The firm has a market cap of £9.35 million, a P/E ratio of -111.00 and a beta of -2.23.
Synairgen Company Profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Read More
- Five stocks we like better than Synairgen
- Financial Services Stocks Investing
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Best Stocks Under $5.00
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
